GeNeuro SA

>GeNeuro SA> is a biotechnology company that was established in >2006> and is focused on developing innovative treatments for inflammatory and neurodegenerative disorders linked with Human Endogenous Retroviruses (HERVs). The company's slogan, >"We focus on Human Endogenous Retroviruses (#HERVs) to fight neurodegeneration in #MS, #ALS and #LongCovid $GNRO,"> highlights their dedication to combat the progression of disability in conditions such as Multiple Sclerosis (#FightMS) and other neurodegenerative diseases (#ALS #LongCOVID). In >February 2024>, GeNeuro SA secured a >€5.00M> post-IPO equity investment, with >Servier> and >Institut Merieux> as the primary investors. This funding is a testament to the company's potential and the confidence that reputable investors have in their vision and mission. As a company operating in the >Biotechnology> and >Health Care> sectors, GeNeuro SA is actively contributing to the advancement of treatments for critical medical conditions. Their commitment to addressing the challenges posed by neurodegenerative disorders associated with HERVs underscores their determination to make a meaningful impact in the healthcare industry.